Cetuximab and Envafolimab Plus mFOLFOXIRI as First-line Treatment for RAS/BRAF Wild-type, MSS, Unresectable Left-side Metastatic Colorectal Cancer

Cetuximab and Envafolimab Plus mFOLFOXIRI as First-line Treatment for RAS/BRAF Wild-type, MSS, Unresectable Left-side Metastatic Colorectal Cancer is a phase 2, randomised interventional study registered as NCT05959356 by Sun Yat-sen University, with a registry enrolment figure of 198 participants, started 2023-11-09 and due to reach its primary completion in 2026-12-31. Interventions recorded: Cetuximab + Envafolimab + mFOLFOXIRI; Cetuximab + mFOLFOX6. Conditions listed: Metastatic Colorectal Cancer. Primary outcome: Progression free survival. Colorectal eligibility wording from the registry: "* Patients have histologically or cytologically confirmed RAS and BRAF wild-type, MSS metastatic colorectal adenocarcinoma (mCRC), excluding appendiceal and anal cancers". Sites: China. No results are recorded here; the registry entry is the source.